Hofseth BioCare ASA Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
For the nine months, sales was NOK 144.93 million compared to NOK 85.28 million a year ago. Revenue was NOK 171.09 million compared to NOK 86.84 million a year ago. Net loss was NOK 54.79 million compared to NOK 99.17 million a year ago. Basic loss per share from continuing operations was NOK 0.14 compared to NOK 0.27 a year ago. Diluted loss per share from continuing operations was NOK 0.14 compared to NOK 0.27 a year ago.